Program
follitropin alfa
Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.
Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.
Drug pageFollitropin alfa: every studyMany companies study it; this page follows only the 23 they lead. All 49 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germanyits history only | 131 open or running | phase 4since Nov 4, 2005 | Nov 4, 2005 | Sep 30, 2027phase 3 · NCT07340827 |
| IVFarmaits history only | 20 open or running | phase 3since Mar 2, 2017 | Mar 2, 2017 | none ahead |
| Bharat Serums and Vaccinesits history only | 11 open or running | phase 3since Jan 23, 2022 | Jan 23, 2022 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 10 open or running | phase 3since Jan 5, 2015 | Jan 5, 2015 | none ahead |
| Fertility Biotechits history only | 10 open or running | phase 1since May 19, 2015 | May 19, 2015 | none ahead |
| Finoxits history only | 10 open or running | phase 3since May 10, 2010 | May 10, 2010 | none ahead |
| Gema Biotechits history only | 10 open or running | phase 3since May 22, 2015 | May 22, 2015 | none ahead |
| IBSA Institut Biochimiqueits history only | 10 open or running | phase 3since Sep 15, 2006 | Sep 15, 2006 | none ahead |
| MinaPharm Pharmaceuticalsits history only | 10 open or running | phase 4since Nov 30, 2016 | Nov 30, 2016 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 1since Mar 4, 2025 | Mar 4, 2025 | none ahead |
Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Nov 4, 2005.
- Dec 20, 2011Phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT01497197 · 174 enrolled · United Arab Emirates
- Jun 4, 2013Phase 4 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT01871532 · 24 enrolled · Ireland, United Kingdom
- Jan 5, 2015Changchun GeneScience Pharmaceutical’s first study: phase 3 study in AnovulationNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT02335879 · 534 enrolled
- May 19, 2015Fertility Biotech’s first study: phase 1 study in Healthy VolunteersNew to Fertility BiotechFertility Biotech · NCT02459418 · 42 enrolled · United Kingdom
- May 22, 2015Gema Biotech’s first study: phase 3 study in InfertilityNew to Gema BiotechGema Biotech · NCT02454556 · 106 enrolled · Argentina
- Nov 30, 2016MinaPharm Pharmaceuticals’ first study: phase 4 study in Infertility, FemaleNew to MinaPharm PharmaceuticalsMinaPharm Pharmaceuticals · NCT03057574 · 200 enrolled · Egypt
- Mar 2, 2017IVFarma’s first study: phase 3 study in Infertility, FemaleNew to IVFarmaIVFarma · NCT03088137 · 118 enrolled · Russian Federation
- Feb 26, 2019Phase 1 study in Area Under CurveIVFarma · NCT03857230 · 28 enrolled · Russian Federation
- May 19, 2021Phase 1 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT04899193 · 72 enrolled · China
- Jan 23, 2022Bharat Serums and Vaccines’ first study: phase 3 study in Infertility, FemaleNew to Bharat Serums and VaccinesBharat Serums and Vaccines · NCT05266924 · 250 enrolled · India
- Mar 4, 2025Qilu Pharmaceutical’s first study: phase 1 study in Infertility, FemaleNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06864793 · 48 enrolled · China
- Jul 15, 2025Phase 1 study in HypogonadismMerck KGaA, Darmstadt, Germany · NCT07097259 · 55 enrolled · United States
- Nov 17, 2025Phase 1 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07269327 · 24 enrolled · United Kingdom
- Jan 6, 2026Phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07340827 · 266 planned · Japan
Ahead
- Sep 30, 2027Primary completion: phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07340827
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Follicle Stimulating Hormonerule | glycotope-gmbh | phase 4 | 6 |
| follitropin deltarule | Ferring Pharmaceuticals | phase 3 | 18 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07340827Infertility · Japan | 3 | Recruiting | Merck KGaA, Darmstadt, Germany | Sep 30, 2027 | 266 |
| NCT07269327Infertility · United Kingdom | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 9, 2026 | 24 |
| NCT07097259Hypogonadism · United States | 1 | Completed | Merck KGaA, Darmstadt, Germany | Dec 23, 2025 | 55 |
| NCT06864793Infertility, Female · China | 1 | Active, not recruiting | Qilu Pharmaceutical | Feb 4, 2026 | 48 |
| NCT05266924Infertility, Female · India | 3 | Active, not recruiting | Bharat Serums and Vaccines | Aug 31, 2023 | 250 |
| NCT04899193Infertility · China | 1 | Completed | Merck KGaA, Darmstadt, Germany | May 28, 2022 | 72 |
| NCT03857230Area Under Curve · Russian Federation | 1 | Completed | IVFarma | May 10, 2016 | 28 |
| NCT03088137Infertility, Female · Russian Federation | 3 | Completed | IVFarma | Aug 17, 2018 | 118 |
| NCT03057574Infertility, Female · Egypt | 4 | UNKNOWN | MinaPharm Pharmaceuticals | Dec 2017 | 200 |
| NCT02454556Infertility · Argentina | 3 | Completed | Gema Biotech | Dec 2016 | 106 |
| NCT02459418Healthy Volunteers · United Kingdom | 1 | Completed | Fertility Biotech | May 19, 2016 | 42 |
| NCT02335879Anovulation | 3 | Completed | Changchun GeneScience Pharmaceutical | Aug 2009 | 534 |
| NCT01871532Infertility · Ireland, United Kingdom | 4 | Terminated | Merck KGaA, Darmstadt, Germany | Mar 2014 | 24 |
| NCT01497197Infertility · United Arab Emirates | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Jan 2014 | 174 |
| NCT01183143Infertility · Germany | 3 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2, 2006 | 215 |
| NCT01185782Infertility · Japan | 3 | Completed | Merck KGaA, Darmstadt, Germany | Dec 2007 | 300 |
| NCT01121666Infertility · Austria, Denmark, Germany and more | 3 | Completed | Finox | Dec 2011 | 460 |
| NCT01081626Infertility · Kuwait, Lebanon, Saudi Arabia | 4 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2011 | 310 |
| NCT01081639Infertility | 3 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2004 | 34 |
| NCT01071200Helping Behavior · Italy | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 2009 | 133 |
| NCT00829244Infertility · Switzerland | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2010 | 200 |
| NCT00378001Infertility · United States | 3 | Completed | IBSA Institut Biochimique | May 2006 | 152 |
| NCT00249834Infertility · France | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jan 16, 2006 | 166 |
How it is read
Names in the registry
- “Gonal-f”, 2 entries
- “Follitropin alfa (Primapur)”, 2 entries
- “Gonal-f®”, 2 entries
- “GONAL-f®”, 2 entries
- “GONAL f® prefilled pen”, 2 entries
Conditions, from the studies’ own filings
- Infertility, 15 studies
- Infertility, Female, 5 studies
- Hypogonadism, 1 study
- Anovulation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.